NCT04262544

An Innovative Mobile Health Intervention to Improve Self-care in Patients With Heart Failure

Completed NA Last updated 28 April 2023

What this trial tests

NA trial testing iCardia4HF in Heart Failure in 89 participants. Completed in 31 December 2022.

Timeline

20 February 2020

Primary endpoint
30 September 2022

31 December 2022

Quick facts

Lead sponsor	University of Illinois at Chicago
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	89
Start date	20 February 2020
Primary completion	30 September 2022
Estimated completion	31 December 2022
Sites	1 location across United States

Drugs / interventions tested

• iCardia4HF
• Usual Care

Conditions studied

• Heart Failure — all drugs for Heart Failure →

Sponsor

University of Illinois at Chicago

Who can join

18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Heart failure (HF) is associated with high mortality and hospitalization rates. Prior studies show that adherence to routine HF self-care behaviors reduces the risk of all-cause mortality and HF-related hospitalizations, and improves health related quality of life. However, self-care has generally been found to be poor among HF patients. This study aims to assess the feasibility, acceptance, and efficacy of an innovative, patient-centered intervention (iCardia4HF) that aims to promote adherence to HF self-care and improve patient outcomes through the use of commercially available mobile health technologies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Patient-centered mobile health technology intervention to improve self-care in patients with chronic heart failure: Protocol for a feasibility randomized controlled trial.
   Kitsiou S, Gerber BS, Kansal MM, Buchholz SW, et al · · 2021 · cited 14× · PMID 33991686 · DOI 10.1016/j.cct.2021.106433